Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of “Hold” by Analysts

Fate Therapeutics, Inc. (NASDAQ:FATE) has been given a consensus recommendation of “Hold” by the nine research firms that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, five have issued a hold rating and three have issued a buy rating on the company. The average 1-year target price among brokers that have covered the stock in the last year is $3.9167.

Several equities analysts have recently weighed in on FATE shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Fate Therapeutics in a research report on Thursday, January 22nd. HC Wainwright upgraded Fate Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 target price for the company in a research report on Friday, October 31st. Wall Street Zen downgraded Fate Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Finally, Cantor Fitzgerald reiterated a “neutral” rating on shares of Fate Therapeutics in a report on Tuesday, November 4th.

Institutional Investors Weigh In On Fate Therapeutics

Several hedge funds have recently made changes to their positions in the company. Savant Capital LLC purchased a new stake in Fate Therapeutics in the second quarter worth about $27,000. Bridgeway Capital Management LLC purchased a new position in Fate Therapeutics during the second quarter valued at approximately $28,000. Commonwealth Equity Services LLC purchased a new position in shares of Fate Therapeutics in the 4th quarter valued at $26,000. Russell Investments Group Ltd. lifted its stake in shares of Fate Therapeutics by 73.1% during the 3rd quarter. Russell Investments Group Ltd. now owns 28,676 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 12,114 shares during the last quarter. Finally, Corient Private Wealth LLC bought a new stake in Fate Therapeutics during the fourth quarter valued at about $29,000. 97.54% of the stock is currently owned by hedge funds and other institutional investors.

Fate Therapeutics Trading Down 8.6%

Shares of NASDAQ:FATE opened at $1.48 on Thursday. The company has a market cap of $170.72 million, a price-to-earnings ratio of -1.12 and a beta of 2.24. Fate Therapeutics has a 12 month low of $0.66 and a 12 month high of $1.94. The company has a 50-day moving average price of $1.15 and a 200 day moving average price of $1.15.

Fate Therapeutics Company Profile

Fate Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of first‐in‐class cellular immunotherapies for cancer and immune disorders. The company leverages its proprietary induced pluripotent stem cell (iPSC) platform to create off‐the‐shelf natural killer (NK) and T‐cell products designed to overcome limitations of donor‐derived approaches. Fate’s research aims to deliver therapies with consistent quality, increased potency and scalable manufacturing for broad patient access.

Central to Fate’s pipeline are multiple iPSC‐derived cell therapy candidates in active clinical development.